Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on Gamida Cell to $2 from $5 and keeps an Overweight rating on the shares. The firm notes Gamida Cell recorded revenues of $673,000 having delivered two Omisirge units in Q3, and guided to ship 4-6 units this year. Piper now forecasts Omisirge revenues of $1.0M in Q4 totaling $1.68M this year, growing to $13.5M in 2024. Gamida Cell is exploring strategic alternatives to fund full launch of Omisirge, Piper also notes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GMDA:
- Gamida Cell reports Q3 EPS (1c), consensus (17c)
- Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
- Gamida Cell (GMDA) Q3 Earnings Cheat Sheet
- Gamida Cell presents new data on allogeneic stem cell therapy Omidubicel, GDA-20
- Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
